AstraZeneca signs vaccine deal with China’s CanSino
阿斯利康与康希诺签署mRNA疫苗合作协议
Drugmaker says it is working on new technologies to develop vaccines for infectious diseases where there is ‘high unmet need’
该协议表明阿斯利康正在投资于这种在新冠疫情中首次得到验证的技术，而消息宣布后中国药企康希诺股价上涨逾25%。
AstraZeneca has signed a deal with Chinese pharmaceutical company CanSino Biologics to develop potential messenger RNA vaccines, as the company expands its work to include the technology first proven in the Covid-19 pandemic.Shares in CanSino rose more than 25 per cent on Wednesday after the company announced the agreement to provide manufacturing services for the Anglo Swedish drugmaker. The companies did not disclose the value of the deal.
阿斯利康(AstraZeneca)与中国制药公司康希诺生物(CanSino Biologics)签署了一项协议，将开发潜在的mRNA疫苗。目前，阿斯利康正在扩大其研发范围，将这种在新冠疫情中首次得到验证的技术纳入其中。
The agreement is a sign that AstraZeneca is investing in the mRNA technology that was used successfully for the first time in the Covid-19 jabs developed by BioNTech and Pfizer, and Moderna. CanSino has reported positive early results for its mRNA jab.
在康希诺宣布了将为这家英瑞制药商提供生产服务的协议后，其股价周三上涨逾25%。两家公司没有透露这笔交易的价值。
AstraZeneca said it was working on “next generation technologies” to develop vaccines and monoclonal antibodies for infectious diseases where there was “high unmet need”.
该协议表明阿斯利康正在投资于mRNA技术。在BioNTech和辉瑞(Pfizer)联合研发的新冠病毒疫苗以及摩德纳(Moderna)研发的新冠病毒疫苗中，mRNA技术首次被成功应用。康希诺已经报告了其mRNA疫苗的积极早期结果。
